Tamta Makharadze

118 Pushkini Street
Batumi, AJ 6000, Georgia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: June 04, 2026

Extended-Interval Immunotherapy in Advanced Lung Cancer: A Case Report.

Extended-Interval Immunotherapy in Advanced Lung Cancer: A Case Report.

Journal: Cureus

Published: March 08, 2026

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.

Journal: Cancers

Published: January 21, 2026

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 16, 2025

Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab.

Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab.

Journal: Frontiers in oncology

Published: October 08, 2025

First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.

First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.

Journal: JTO clinical and research reports

Published: July 14, 2025

Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.

Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors.

Journal: Frontiers in immunology

Published: June 03, 2025

Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.

Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.

Journal: Cancer treatment and research communications

Published: April 08, 2025

Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy.

Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy.

Journal: Cancer treatment and research communications

Published: January 14, 2025

First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.

First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.

Journal: Cancer communications (London, England)

Published: August 06, 2024

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 05, 2024

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.

Journal: The lancet. Gastroenterology & hepatology

Published: October 02, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026